CHEK1 and neoplasm: In previous studies, a combination of checkpoint kinase 1 inhibitor (CHK1i) and low-dose hydroxyurea (LDHU) has been shown to have tumour-selective toxicity, targeting tumours with elevated levels of replication stress without significant toxicity in normal tissue [16,17].